Poland· PL-100490924
Esperoct
A coagulation factor viii product containing turoctocogum alfa pegylateum, registered in Poland by Novo Nordisk A/S. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor viii is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Coagulation factor viii · ATC B02BD02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Turoctocogum alfa pegylateum
- Manufacturer
- Novo Nordisk A/S
- Country
- Poland (PL)
- ATC code
- B02BD02
- ATC class
- Coagulation factor VIII
- Defined daily dose
- 1 TSD, E
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for coagulation factor viii.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor viii · interactions on record
4 records
- 2 severe
- 2 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- EmicizumabB02BX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor viii in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandEsperoctNovo Nordisk A/S
- SwitzerlandEsperoct
- CzechiaESPEROCTNovo Nordisk A/S, Bagsvaerd
- SwedenEsperoct 1000 IE Pulver och vätska till injektionsvätska, lösningNovo Nordisk A/S
- IrelandEsperoct 1000 IU Powder and solvent for solution for injectionNovo Nordisk A/S
- IcelandEsperoctNovo Nordisk A/S*
- NetherlandsEsperoct 1000 IE, poeder en oplosmiddel voor oplossing voor injectieNovo Nordisk A.S.
- BelgiumEsperoct 1000 IUNovo Nordisk
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Esperoct
- Norway · Esperoct
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf31f351-1d96-4310-b787-dfd0a5362653 GET /v1/drugs/cf31f351-1d96-4310-b787-dfd0a5362653?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "5000 j.m.",
"packaging": "Rpz ¦ EU/1/19/1374/007 ¦ 152350\n1 fiol. 5000 j.m. proszku + 1 amp.-strzyk. + 1 zestaw do wstrzykiwań",
"substance": "Turoctocogum alfa pegylateum 5000 j.m.",
"common_name": "Turoctocogum alfa pegylateum",
"pl_product_id": "100490924",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about coagulation factor viii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.